VaxThera
Research and development
Human vaccine pipeline
- Complete
- Partial or in progress
- Zika
ARBOVax-Z
Technology
ARNm - vector viral
Allies
Wisconsin, UNacional, Minciencias
- Fiebre Amarilla
ARBOVax-YF
Technology
ARNm - vector viral
Allies
Wisconsin, UNacional, Minciencias
- Chikungunya
ARBOVax-C
Technology
ARNm - vector viral
Allies
Wisconsin, UNacional, Minciencias
- Fiebre Amarilla
Syn17D
Technology
ARNm - vector viral
Allies
Codagenix
- Denge
DVax
Technology
Virus vivo atenuado
Allies
Wisconsin
- Influenza aviar
AFluVax
Technology
Vector viral
Allies
Quantoom
- HPV-9
CecoLin9
Technology
Vector viral
Allies
Codagenix
- mPOX
MVAx
Technology
Vector viral
Allies
Quantoom
- SARS-Cov-2/mPOX
UNIVAX
Technology
Vector viral
Allies
NIH · FDA pre-IND
- 820 m²
- Cutting-edge technologies: mRNA and viral vectors
- 10 researchers
- Generation of knowledge
- Completo
- Parcial o en proceso
- Zika
Tecnolgía
ARNm - vector viral
Alaidos
Wisconsin
- 820 m²
- Tecnologías de punta: mRNA y vectores virales
- 10 investigadores
- Generación de conocimiento
- 820 m²
- Tecnologías de punta: mRNA y vectores virales
- 10 investigadores
- Generación de conocimiento
Thanks to the technology and the quality of the laboratory facilities, VaxThera will be able to conduct rigorous research studies; design, produce, and validate vaccine candidates; optimize production processes; and generate high-quality vaccines and biological products for use in preclinical studies.
Ongoing Projects
We have developed a universal vaccine against SARS-CoV-2 using a viral vector platform. In preclinical stages, the vaccine has proven to be safe, immunogenic, and effective against various variants of the virus. This vaccine is currently under evaluation for the initiation of clinical trials.
Vaccines against Zika, Chikungunya, and yellow fever are being developed through a partnership with the University of Wisconsin and the National University of Colombia, with co-funding from Colombia’s Ministry of Science, Technology, and Innovation. Our goal is to develop and evaluate these vaccines up to the preclinical stage, using two technological platforms: viral vectors and mRNA.
In alliance with the University of Wisconsin – Madison, we are evaluating our universal vaccine against COVID -19 (UniVax) to limit the transmission of the virus in multiple animal species and reduce the risk of transmission to people. Likewise, the aim is to develop a formulation that allows the vaccine to be administered orally or intranasally while maintaining its protective properties. This project is funded by the United States Department of Agriculture – USDA.
